PMID- 37391316
OWN - NLM
STAT- MEDLINE
DCOM- 20231113
LR  - 20240405
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
VI  - 17
IP  - 5
DP  - 2023 Oct
TI  - Lower serum zinc level is associated with higher fasting insulin in type 2 
      diabetes mellitus (T2DM) and relates with disturbed glucagon suppression response 
      in male patients.
PG  - 493-498
LID - S1751-9918(23)00102-X [pii]
LID - 10.1016/j.pcd.2023.05.008 [doi]
AB  - AIMS: Zinc ion can play critical role in glycemic control in diabetes mellitus 
      (DM), contributing to both insulin synthesis and secretion. In this study, we 
      aimed to investigate the level of zinc in diabetic patients and its association 
      with glycemic parameters, insulin, and glucagon level. METHODS: 112 individuals 
      (59 cases of type 2DM and 53 non-diabetic controls) were included in this study. 
      Biochemical parameters (FBG, 2hpp, HbA1C), and zinc level in the serum were 
      measured using colorimetric assays. Insulin and glucagon were measured by ELISA 
      method. HOMA-IR, HOMA-B, reciprocal HOMA-B, and Quicki indices were calculated 
      using appropriate formula. For further analysis, patients were divided into two 
      groups: high (>135.5 mug/dl) and low (<135.5 mug/dl) zinc. Glucagon suppression was 
      considered yes if 2hpp glucagon < fasting glucagon. RESULTS: Our results showed 
      that serum Zn level in type 2 DM patients was lower than control (P value=0.02). 
      Patients with lower Zn had higher fasting insulin (P value=0.006) and higher 
      beta-cell activity index (HOMA-B, p value=0.02), however fasting glucagon and 
      parameters of hyperglycemia (FBG, 2hpp, Hba1C) were not different. Moreover, 
      insulin sensitivity and resistance indices (Quicki, HOMA-IR,1/HOMA-IR) showed 
      non-significantly improved status in high Zn group. We found non-significant 
      association between glucagon suppression and Zn level in both genders (N = 39, p 
      value = 0.07), however, it was significant in males (N = 14, p value = 0.02). 
      CONCLUSION: Altogether, our results indicated reduced serum Zn in type 2DM can 
      exacerbate hyperinsulinemia and glucagon suppression (only significant in the 
      male), highlighting its importance in type 2DM control.
CI  - Copyright (c) 2023. Published by Elsevier Ltd.
FAU - Safarzad, Mahdieh
AU  - Safarzad M
AD  - Metabolic Disorders Research Center, Golestan University of Medical Sciences, 
      Gorgan, Iran.
FAU - Jazi, Marie Saghaeian
AU  - Jazi MS
AD  - Metabolic Disorders Research Center, Golestan University of Medical Sciences, 
      Gorgan, Iran; Stem Cell Research Center, Golestan University of Medical Sciences, 
      Gorgan, Iran. Electronic address: marie.saghaeian@goums.ac.ir.
FAU - Kiaei, Mohammadreza
AU  - Kiaei M
AD  - Laboratory Sciences Research Center, Golestan University of Medical Sciences, 
      Gorgan, Iran.
FAU - Asadi, Jahanbakhsh
AU  - Asadi J
AD  - Metabolic Disorders Research Center, Golestan University of Medical Sciences, 
      Gorgan, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230628
PL  - England
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
RN  - 9007-92-5 (Glucagon)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
SB  - IM
MH  - Humans
MH  - Male
MH  - Female
MH  - Glucagon
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Glycated Hemoglobin
MH  - Blood Glucose
MH  - Insulin
MH  - *Hyperinsulinism
MH  - *Insulin Resistance
MH  - Fasting
OTO - NOTNLM
OT  - Glucagon
OT  - Insulin
OT  - Type 2 diabetes mellitus
OT  - Zinc
COIS- Declaration of Competing Interest Authors declare that there are no competing 
      interests in relation to the current study.
EDAT- 2023/07/01 11:41
MHDA- 2023/11/13 06:42
CRDT- 2023/06/30 21:54
PHST- 2023/02/17 00:00 [received]
PHST- 2023/05/29 00:00 [revised]
PHST- 2023/05/30 00:00 [accepted]
PHST- 2023/11/13 06:42 [medline]
PHST- 2023/07/01 11:41 [pubmed]
PHST- 2023/06/30 21:54 [entrez]
AID - S1751-9918(23)00102-X [pii]
AID - 10.1016/j.pcd.2023.05.008 [doi]
PST - ppublish
SO  - Prim Care Diabetes. 2023 Oct;17(5):493-498. doi: 10.1016/j.pcd.2023.05.008. Epub 
      2023 Jun 28.